This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Amag-Allos: Worst Bio-Merger in History

Updated with more deal information.

LEXINGTON, Mass. ( TheStreet) -- Amag Pharmaceuticals (AMAG - Get Report) is merging with Allos Therapeutics (ALTH) in what might be the nuttiest, most nonsensical business combination in biotech history.

The only thing Amag and Allos have in common is that they've largely failed initial efforts to sell their respective drugs, neither of which have anything to do with each other.

Amag's commercial launch of Feraheme, an injectable iron replacement therapy for anemia in patients with chronic kidney disease, has been a major disappointment. The same can be said for Allos' lymphoma cancer drug Folotyn.

Ideally, mergers bring together two companies that can capitalize on their respective strengths to make the sum better, stronger, more capable than the individual parts. Wednesday's merger of Amag and Allos does no such thing. It's just two disparate and under-performing biotech companies getting hitched to, at best, save some money.

"We are very excited about this merger as it creates a combined company with an enhanced commercial presence in attractive market segments supported by a more efficient organizational structure," said Brian Pereira, CEO of Amag in a statement that fails on so many levels to rationalize this deal.

Pereira, by the way, will retain the CEO title in the as-yet-unnamed combined company.

Under terms of the deal, Allos shareholders will receive a fixed ratio of 0.128 shares of Amag common stock for each share of Allos common stock they own. At Amag's Tuesday closing price of $19.07, the deal values Allos at $2.44 a share, or $260 million total.

Allos shares closed Tuesday at $2.06 a share.

Allos received U.S. approval for Folotyn in September 2009. At that time, Allos shares traded for around $8 a share. That was basically the high point for Allos's stock price.

Amag's Feraheme was approved in the U.S. in July 2009 when Amag shares traded around $56 a share. Like Allos, Amag' stock price never saw brighter days. The stock fell steadily as Feraheme sales lagged expectations.

The merger of Amag and Allos: Not exactly a match made in heaven.

--Written by Adam Feuerstein in Boston.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AMAG $60.01 -0.56%
AAPL $130.28 0.47%
FB $81.53 -1.07%
GOOG $565.06 3.30%
TSLA $218.42 -0.08%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs